With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.
Using multiple samples from more than 60,000 individuals at a participating hospital, the firm tracks circulating molecules over time in relation to cancer.
The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.
The company expects Medicare coverage for its test to extend to intermediate prostate cancer patients this year, and it believes new data will help drive increased adoption.
The company is developing a non-invasive test that analyzes only a small area of the genome to infer overall tumor mutational load to help guide immunotherapy use.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
MD Anderson aims to rapidly collect clinical utility data to support decisions by relevant committees to broadly offer the test and to begin persuading payors to reimburse.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.